Zhengye Biotechnology Holding Ltd. (ZYBT) AI Stock Analysis

• Market Cap: $45.28M
• Dividend Yield: N/A
• Average Volume (3M): 871.70K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.60
• Revenue Growth: -18.78%
• EPS Growth: -194.62%
• Country: US
• Employees: 278
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 47,391,376
• 10 Day Avg. Volume: 198,467
• 30 Day Avg. Volume: 871,704
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 38.45
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $0.88 ▼(-21.77% Downside)
• Action: Reiterated Date: 12/31/25
• Date: Action: Reiterated 12/31/25

The score is held back primarily by very weak technicals (price below all key moving averages, negative MACD, RSI at 17) and pressured cash flow (free cash flow down 63.72%). A moderately stable balance sheet (debt-to-equity 0.30) partially offsets these risks, while valuation is difficult to support due to a negative P/E and no dividend yield provided.

Positive Factors

Moderate Leverage

A debt-to-equity of 0.30 and a strong equity ratio indicate balance-sheet flexibility and lower refinancing risk. Over 2-6 months this supports continued R&D and operating investments without urgent capital raises, preserving strategic optionality for partnerships or product development.

Negative Factors

Declining Revenue

Double-digit revenue decline and negative multi-period growth highlight a shrinking top line. Persisting contraction reduces scale benefits, pressures long-term investment capacity, and can force reprioritization of development programs or cuts to commercial expansion.

Zhengye Biotechnology Holding Ltd. Business Overview & Revenue Model

Company Description

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its pr...

Read more

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its pr...

How the Company Makes Money

ZYBT generates revenue through multiple streams, primarily by selling its biopharmaceutical products to healthcare providers and institutions. The company also earns income from licensing agreements for its proprietary technologies and innovations...

Read more

ZYBT generates revenue through multiple streams, primarily by selling its biopharmaceutical products to healthcare providers and institutions. The company also earns income from licensing agreements for its proprietary technologies and innovations...

Zhengye Biotechnology Holding Ltd. Financial Statement Overview

Breakdown	Jun 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	186.36M	211.65M	260.27M	214.07M
Gross Profit	91.30M	129.85M	153.52M	125.39M
EBITDA	42.60M	72.10M	85.55M	70.12M
Net Income	11.31M	31.46M	46.73M	38.96M
Balance Sheet
Total Assets	493.25M	499.89M	519.67M	445.28M
Cash, Cash Equivalents and Short-Term Investments	20.04M	16.30M	9.75M	6.28M
Total Debt	86.43M	89.85M	64.88M	30.00M
Total Liabilities	140.71M	160.62M	162.81M	126.44M
Stockholders Equity	283.96M	272.85M	296.50M	267.47M
Cash Flow
Free Cash Flow	13.27M	36.58M	-9.99M	5.41M
Operating Cash Flow	41.05M	48.18M	17.34M	31.81M
Investing Cash Flow	-27.66M	-11.77M	-27.33M	-26.27M
Financing Cash Flow	-22.13M	-18.98M	13.46M	-3.05M

Zhengye Biotechnology Holding Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.13
• 50DMA: Negative
• 100DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZYBT, the sentiment is Negative. The current price of 1.13 is below the 20-day moving average (MA) of 2.63, below the 50-day MA of 6.15, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -1.00 indicates Negative momentum. The RSI at 35.40 is Neutral, neither overbought nor oversold. The STOCH value of 14.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZYBT.

Zhengye Biotechnology Holding Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZYBT	52 Neutral	$45.28M	―	4.06%	―	-18.78%	-194.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
UPC	46 Neutral	$1.77M	>-0.01	2.66%	―	-27.81%	―
CPHI	45 Neutral	$25.12M	―	-43.00%	―	-26.92%	69.90%
SHPH	―	$4.19M	-0.25	-9999.00%	―	―	79.31%